Multiple sclerosis and the Epstein-Barr virus: what the evidence shows
How a 20-year study of military personnel tied multiple sclerosis to a common virus, why most infected people never develop the disease, and where vaccine and treatment trials stand.

Multiple sclerosis is a disease in which the immune system attacks myelin, the insulation around nerve fibers in the brain and spinal cord. An analysis of insurance claims estimated that between about 850,000 and 914,000 people in the United States were living with it in 2017, and that it is nearly three times as common in women as in men (Wallin et al., 2019).
The Epstein-Barr virus infects most people at some point, often in childhood without symptoms. In teenagers and adults it can cause infectious mononucleosis. The virus then stays in the body for life. For decades researchers suspected a connection with multiple sclerosis. A 2026 review in The Lancet Neurology concluded that the evidence now strongly supports the idea that Epstein-Barr infection is, in most cases, necessary for the disease to develop (Lünemann and Münz, 2026).
This article is for people with multiple sclerosis, their families, and anyone who wants to understand what this finding does and does not mean.
The military study
The strongest evidence came in 2022. Researchers used blood samples that the U.S. military collects routinely from active-duty personnel and stores. Among more than 10 million people, 955 were diagnosed with multiple sclerosis during their service (Bjornevik et al., 2022).
The researchers focused on people who had not yet been infected with Epstein-Barr virus when their first sample was taken. Thirty-five of those who later developed multiple sclerosis were in this group, and all but one of them became infected before their disease began. The risk of multiple sclerosis increased 32-fold after Epstein-Barr infection. It did not increase after infection with other viruses, including cytomegalovirus, which spreads in a similar way (Bjornevik et al., 2022).
Blood levels of neurofilament light chain, a protein released when nerve fibers are damaged, began to rise only after Epstein-Barr infection (Bjornevik et al., 2022). That timing matters because it argues against the possibility that early, silent multiple sclerosis made people more prone to infection.
An earlier study in the same military database had pointed the same way. All 10 people who were uninfected at the start and later developed multiple sclerosis became infected first, compared with 35.7 percent of matched controls over the same period (Levin et al., 2010). A meta-analysis of 18 studies also found that people who have had infectious mononucleosis are about twice as likely to develop the disease (Handel et al., 2010).
What the study does and does not show
This was an observational study. Nobody was assigned to be infected, so it cannot prove cause in the way a randomized trial can. Its strength is the order of events. Infection came first, signs of nerve damage came next, and the diagnosis followed. The 32-fold increase is also much larger than the increases linked to other known risk factors.
The study was done in young adults serving in the military, who are healthier than the general population and mostly male. That limits how far the exact numbers can be applied. The link between the virus and the disease has, however, been a strong and consistent finding in studies of other groups (Lünemann and Münz, 2026).
Why most infected people never get it
The virus is close to universal and multiple sclerosis is uncommon, so infection alone is not enough. Something else must separate the small number who develop the disease.
Part of the answer is genetic. The 2026 review describes evidence that the virus interacts with genes known to raise the risk of multiple sclerosis and changes the behavior of B cells, the immune cells it lives in (Lünemann and Münz, 2026).
Another part may be how well each person's immune system keeps a particular reaction in check. A 2023 study found that some people carry immune cells that react both to the virus and to a brain protein, and that whether these cells are eliminated depends on inherited differences in natural killer cells and on the strain of virus (Vietzen et al., 2023).
Low vitamin D levels, smoking, and obesity in adolescence are also known to raise the risk.
How a virus could cause the damage
The leading explanation is mistaken identity. One group studied antibodies from the spinal fluid of people with multiple sclerosis and found that some of them bind both a protein from the Epstein-Barr virus and GlialCAM, a protein made by cells in the brain and spinal cord. The two proteins share a similar stretch of structure, so an immune response aimed at the virus can also hit nerve tissue (Lanz et al., 2022).
This fits with how the most effective current drugs work. Ocrelizumab removes B cells from the blood. In two phase 3 trials it lowered the relapse rate by 46 and 47 percent compared with an older drug, interferon beta-1a. It also reduced the share of patients whose disability worsened, 9.1 percent compared with 13.6 percent (Hauser et al., 2017). That does not prove the virus is the reason these drugs work, but it is consistent with it.
How multiple sclerosis is treated now
Current treatment relies on disease-modifying drugs that calm or redirect the immune system. They reduce relapses and slow the build-up of disability, especially when started early. They do not cure the disease or repair damage that has already happened. A treatment aimed at the virus would work in a different way, which is one reason this research has drawn so much attention.
Treatments aimed at the virus
Several approaches are being tested.
- T-cell therapy. In a phase 1 trial, 13 people with progressive multiple sclerosis received their own immune cells after the cells had been trained in the laboratory to target Epstein-Barr virus. There were no serious adverse events, and 7 of the 10 who completed treatment improved (Pender et al., 2018). All six who received cells that reacted strongly to the virus improved, compared with one of the four whose cells reacted weakly. The trial was small and had no comparison group.
- Vaccines given to people who already have the disease. A phase 2 trial called Horizon is testing an mRNA vaccine against the virus in 180 people diagnosed with multiple sclerosis within the past two years. It will look first at safety and then at whether the vaccine reduces new disease activity (University of Edinburgh).
- Vaccines to prevent infection in the first place. If a vaccine could stop people from catching the virus, it might prevent multiple sclerosis, but it would take many years to find out.
Antiviral drugs are also under discussion (Lünemann and Münz, 2026).
Practical points
- Nearly every adult carries the virus, so a positive Epstein-Barr antibody test says nothing about a person's risk and is not useful for diagnosing multiple sclerosis.
- Nothing in this research changes current treatment. Starting an effective disease-modifying drug early remains the main way to prevent relapses and disability.
- Having had mononucleosis raises the risk only slightly in absolute terms. The great majority of people who have had it never develop multiple sclerosis.
- If you are interested in a vaccine or treatment trial, ask your neurologist which studies are recruiting.
When to see a doctor
See a doctor promptly for loss of vision or pain in one eye, double vision, numbness or weakness that lasts more than a day, or new problems with balance. These can be early signs of multiple sclerosis and of other conditions that need treatment.
Sources
- The prevalence of MS in the United States: A population-based estimate using health claims data (Wallin et al., Neurology, 2019) — analysis of health insurance claims
- Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies (Lünemann and Münz, The Lancet Neurology, 2026) — review
- Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis (Bjornevik et al., Science, 2022) — cohort study of more than 10 million U.S. military personnel, 955 cases
- Primary infection with the Epstein-Barr virus and risk of multiple sclerosis (Levin et al., Annals of Neurology, 2010) — nested case-control study, 305 cases and 610 controls
- An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis (Handel et al., PLoS One, 2010) — meta-analysis of 18 studies
- Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis (Vietzen et al., Cell, 2023) — immunology study
- Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM (Lanz et al., Nature, 2022) — laboratory study of antibodies from spinal fluid
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis (Hauser et al., New England Journal of Medicine, 2017) — two randomized phase 3 trials
- Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis (Pender et al., JCI Insight, 2018) — phase 1 trial, 13 participants
- UK vaccine trial targets virus linked to MS (University of Edinburgh) — announcement of the phase 2 Horizon trial
This article is for general information and is not medical advice. Talk to your doctor before changing a medication, treatment or exercise program.



